Friday, 21 Sep 2018

You are here

NHANES Survey Shows OA Rising and RA Declining

An analysis of 43,706 adults from the 1999-2014 National Health and Nutrition Examination Surveys (NHANES) demonstrated temporal trends in the prevalence of arthritis, including a rise in osteoarthritis (OA) from 6.6% to 14.3%, while the prevalence of rheumatoid arthritis (RA) decreased from 5.9% to 3.8% in the USA, (Citation source https://buff.ly/2o6fhkW

Overall the age-adjusted prevalence of self-reported doctor diagnosed arthritis was 24.7%, and did not change significantly over time. OA was most prevalent ( 9.7%) and RA was next at 4.2%;

Increase in OA prevalence was significant in both genders; in non-Hispanic Whites, non-Hispanic Blacks, and Hispanics; and in people with high socioeconomic status.

Decrease in RA prevalence was more pronounced in men, non-Hispanic Blacks, and participants with low income or obesity.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Treat-to-Target in RA: No Increase in AEs

Implementing a treat-to-target approach for the care of rheumatoid arthritis (RA) did not result in an increase in adverse events or resource use, a post-hoc analysis of a randomized trial showed.

Mediterranean Diet Reduces Risk of Rheumatoid Arthritis

High adherence to a Mediterranean diet appears to be associated with a lower risk of rheumatoid arthritis (RA), especially in men and those who are seropositive, according to a study published in Arthritis Research & Therapy.

Early Exposure to Passive Smoke May Up Risk for RA Later in Life

Exposure to second-hand smoke during childhood was associated with an increased risk for developing rheumatoid arthritis (RA) later in life, researchers said.

Tumor Necrosis Factor Inhibitors Do Not Increase the Risk of Cancer Recurrence

There is a large body of data that shows tumor necrosis factor inhibitors (TNFi) use in rheumatoid arthritis (RA) confers the same risk as that seen in RA - meaning there is no increase over and above that incurred by inflammation and RA itself.  There are fewer studies about whether it is safe to use a TNFi in someone with a pre-existing history of cancer.

Cardiovascular Benefits of Maintaining Biologic Therapy

An Australian prospective study of patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) has shown that sustained use of tumour necrosis factor (TNFi) inhibitors or biologics can reduce the risks of cardiovascular events (CVEs).